ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0357

Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)

Jason Xenakis1, Esther Yi1, Iyar Mazar2, Sarah Knight3, Harriet Makin3, Samantha Wratten3, Rohit Aggarwal4 and Stephanie McKee3, 1Pfizer Inc., New York, United States of America, New York, 2Pfizer, US, New York, 3Clarivate, London, United Kingdom, 4University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

Meeting: ACR Convergence 2025

Keywords: Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Polymyositis (PM) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by muscle inflammation and muscle weakness. Extra muscular manifestations like interstitial lung disease (ILD), joint pain or skin rashes may also be experienced. This study aimed to evaluate the content validity of patient-reported outcome (PRO) measures used in PM (encompassing ASyS, OM, Others, IMNM), i.e., whether the content of these measures 1) captures symptoms or impacts that are important to adults with PM and 2) is comprehensible to respondents.

Methods: Adult (≥18 years) patients in the US with a clinical diagnosis of PM were recruited by a clinical site to take part in individual, semi-structured, 90-minute online interviews conducted from September 2023 to June 2024. Osteoarthritis, fibromyalgia, neurological disorders, cardiac conditions, and lung conditions unrelated to IIM were excluded. The IRB-approved interview guide included open-ended questions to explore the content validity (i.e., relevance, comprehensiveness, and comprehensibility) of 8 PRO measures which assess physical functioning, fatigue and disease activity (Table 1). Participants were also asked about their perceptions of meaningful changes in scores. Purposive sampling with recruitment targets were used to recruit a diverse sample in terms of age, sex, race, ethnicity, and education level. Interviews were audio-recorded, transcribed, anonymized and analyzed using qualitative framework analysis in Atlas.ti v9.

Results: Participants were mostly female (n=21/34, 62%) and/or white (n=30/34, 88%) with a mean age of 58 years (range 32 – 77 years). Most participants had a graduate/postgraduate (n=14/34, 41%) or bachelor’s degree (n=10/34, 29%). Due to time constraints, not all measures were debriefed by all participants.An overview of findings is presented in Table 1. The instructions and item wording were interpreted as intended by the majority of participants for all PRO measures debriefed. The measures were conceptually relevant to the majority of the sample. Most participants interpreted the recall periods correctly. The response options/scales were correctly interpreted by participants. Participant feedback indicated that none of the suggested changes were critical for understanding.Meaningful change was assessed at the item level for multi-item PRO measures. For the HAQ-DI and the PROMIS-PF items, participants considered an improvement of 1- or 2-points as meaningful. A 2-point improvement on FACIT-Fatigue item(s) was considered meaningful to most participants.A 2-point improvement on the single-item PGA-NRS and PGIC-PA, or 1-point worsening on the PGA-NRS was considered by most participants to be meaningful. A 1-point improvement or worsening on the PGA-VRS and PGIS-PA was considered meaningful.

Conclusion: All 8 PRO measures demonstrated content validity for use in research with adults with PM. For multi-item and single-item PROs, a 1- to 2-point item-level change was considered meaningful, demonstrating the value of small improvements for individuals with this debilitating condition. These insights are valuable for interpreting quantitative within-patient changes when evaluating treatments for PM.

Supporting image 1Table 1. Overeview of findings from cognitive debriefing interviews


Disclosures: J. Xenakis: Pfizer, Inc., 3, 11; E. Yi: Pfizer, Inc., 3, 11; I. Mazar: Pfizer, Inc., 3, 11; S. Knight: Clarivate Analytics, 3, 11; H. Makin: Clarivate Analytics, 3, 11; S. Wratten: Clarivate, 3, 11; R. Aggarwal: Alexion, 2, ANI Pharmaceuticals, 2, Argenx, 2, Artasome, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, CabalettaBio, 2, Capella, 2, Capstanx, 2, CSL Behring, 2, EMD Serono, 2, 5, Galapagos, 2, Horizon Therapeutics, 2, I-Cell, 2, Immunovant, 2, Janssen, 2, 5, Kezar, 2, Kyverna, 2, Lilly, 2, Manta Medicines, 2, Nkarta, 2, Novartis, 2, Octapharma, 2, Pfizer, 2, 5, Priovant, 2, 5, Teva, 2, Tourmaline Bio, 2, UCB, 2, Verismo Therapeutics, 2; S. McKee: Clarivate, 3, 11.

To cite this abstract in AMA style:

Xenakis J, Yi E, Mazar I, Knight S, Makin H, Wratten S, Aggarwal R, McKee S. Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM) [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/content-validation-of-patient-reported-outcome-pro-measures-for-fatigue-physical-function-and-disease-activity-in-polymyositis-pm/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/content-validation-of-patient-reported-outcome-pro-measures-for-fatigue-physical-function-and-disease-activity-in-polymyositis-pm/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology